A week after a report suggested that the Department of Defense had paid full retail price for EpiPens — to the tune of $54 million in overcharges — because the drug’s maker, Mylan, misclassified the live-saving medication, preventing the government from receiving proper rebates, lawmakers are calling on the drugmaker to reimburse those costs. [More]
